Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has announced the immediate appointment of Nelson Cabatuan as its new Chief Financial Officer. Cabatuan brings over 15 years of experience in the life sciences industry to Lexaria, where he will oversee financial operations and support the company’s growth strategy, particularly in maximizing the potential of their DehydraTECH platform. Lexaria is known for its patented DehydraTECH technology which enhances drug delivery through oral intake and has a strong IP portfolio with multiple patents granted and pending.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
